Search results

Technologies 44

View all

• AminoX: Making Biologics Safer with Synthetic Biology and Advanced Chemistry
  AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition.
• DNA Nanoswitches: “Lab-on-a-Molecule” Drug Discovery
  The Lab-on-a-Molecule platform leverages the Wyss Institute’s DNA nanotechnology technology for the high-throughput, low-cost screening of a wide range of chemical and biologic compounds to enable the discovery of first-in-class therapeutics for various conditions.
• Pancreatitis Tx: An Engineered Protein Treatment for Pancreatitis
  First disease-modifying therapy that can be systemically applied to safely and effectively treat patients with different forms of pancreatitis.
• FeCILL: Targeted Treatment for Severe Fungal Infections
  FeCILL is novel delivery vehicle for antifungal drugs that targets them right to the infection site and reduces harmful side effects in patients with severe fungal infections.
• Metabolically Labeled CAR-T Cells Against Cancer
  Through a simple and effective metabolic labeling approach, patient-derived T cells engineered to carry immune-enhancing cytokines on their surfaces could help expand adoptive T cell therapies to treatment of solid tumors and improve blood cancer therapies.
• DoriVac: Boosting Antigen-specific Immune Responses with DNA Origami-Based Vaccines
  Personalized cancer and infectious disease vaccine platform harnessing DNA nanotechnology to control the co-delivery and co-presentation of tumor antigen and adjuvant ligands to immune cells with nanoscale precision. This approach has potential to trigger enhanced immune responses against tumors and infectious pathogens.

Collaborations 4

• Brigham-Wyss DxA
  The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests.
• Biomarker Discovery Laboratory (BDL)
  Bridging the diagnostic gap from biomarker discovery to market-ready test kits and instruments through cutting-edge technology development and clinical collaboration.
• Brain Targeting Program
  Pre-competitive multi-partner industry collaboration that aims to identify novel transport targets and shuttle compounds to enable more effective delivery of drugs to the brain.
• i3 Center: Biomaterials to Create T Cell Immunity
  Cancer immunologists and biological engineers are developing new biomaterials-based approaches to develop new anti-cancer immunotherapies for treatment-resistant cancers.

News 256

View all

• Awards
  
  Wyss Institute at Harvard University wins BARDA contract to leverage human Organ Chips to advance knowledge and drug discovery for broad range of health security threats
  October 18, 2023
• Press Release
  
  Human Lung Chip leveraged to faithfully model radiation-induced lung injury
  October 17, 2023
• Press Release
  
  Adding immunity to human kidney-on-a-chip advances cancer drug testing
  August 23, 2023

Multimedia 72

View all

• 

  Video/Animation
  Genetic & Cellular Engineering w/ David Schaffer & Samir Mitragotri – BIOS Roundtable
  Samir Mitragotri is a Core Faculty member at the Wyss Institute and the Hiller Professor of Bioengineering & Hansjorg Wyss Professor of Biologically Inspired Engineering at Harvard SEAS. David Schaffer is Professor at UC Berkeley & Director at BBH. The two discuss Genetic and Cellular Engineering, with a focus on delivery challenges.

• 

  Video/Animation
  Bridging science, engineering, and art: from mechanobiology to Human Organs-on-Chips
  In this Marsilius Lecture, Wyss Founding Director Don Ingber shares his personal path from a serendipitous experience in an undergraduate art class that led to his discovery of how living cells are constructed using “tensegrity” architecture and how this contributed to the birth of the field of Mechanobiology to his more recent work on human...

• 

  Video/Animation
  How can we better treat brain diseases?
  The Brain Targeting Program at the Wyss Institute is a pre-competitive, multi-partner industry collaboration that aims to identify novel transport targets and shuttle compounds to enable more effective delivery of drugs to the brain. Credit: Wyss Institute at Harvard University

• 

  Audio/Podcast
  Reimagining Infertility – An Interview with Christian Kramme
  Christian Kramme imagines a world where all people can have a child on their own time frame. Such “reproductive autonomy” is not the case today – infertility is a growing problem worldwide, and existing treatments like IVF are incredibly taxing on women’s bodies and too expensive for most of the global population to access. Listen...

• 

  Video/Animation
  FeCILL: Reimagining How We Treat the Sickest Patients
  Opportunistic fungal infections usually only affect patients whose immune systems are compromised, but when they do, they are often deadly – the mortality rate for these infections can be as high as 25%. Existing antifungal treatments have high levels of toxicity, and can harm the patient more than they help. Researchers at the Wyss Institute...

• 

  Video/Animation
  Metabolic T cell Labeling: simple and effective enhancement of therapeutic T cells with immune-stimulating cytokines
  This animation shows how the surface of patient-derived T cells is metabolically labeled with azido-sugar molecules that then can be used to attach immune-enhancing cytokines with the help of click chemistry. The approach could help expand adoptive T cell therapies to treatment of solid tumors. Credit: Wyss Institute at Harvard University